This is a snippet of the transcript, sign up to read more.
In the non-acute world, for a company like Medline, if a hospital theoretically decided to buy every single product possible from Medline, converting from companies like Johnson & Johnson or Stryker to Medline brand, you might achieve about 58% Medline brand penetration within that hospital. Medline doesn't have sutures or surgical implants, so depending on the hospital's acuity and complexity, you can reach the high 50s percentage-wise for Medline brand. That's where the profit lies in vertical integration, with self-manufactured and private label products.
This is a snippet of the transcript, sign up to read more.
An interesting benchmark for you, is that Medline and all the big distributors lose money on just the distribution. Distribution costs, depending on complexity, such as low unit measure distribution and logistics concerns, are around 7%. This includes warehousing and trucking, costing Medline or Cardinal about 7% of revenue. However, the distribution rates charged to hospitals are often below 1%, resulting in a negative 6% on distribution alone. While there is some back-end funding, like Johnson & Johnson paying two points below the line for sutures, you still can't beat the math—you're still underwater.
This is a snippet of the transcript, sign up to read more.
So why would any company do that? Because controlling the channel allows you to profit from your own self-manufactured or private label products. A distribution deal for Medline typically breaks even around a 30% Medline brand ratio. There are factors like margin and what you're selling on exam gloves and surgical packs, but as a rule of thumb, 30% is the breakeven point. At Medline, if it's less than 30% Medline brand, you're not making money on the deal, and it could be a loss. After 30%, it starts to be profitable, and at about 40% Medline brand, you have a really good, mature, profitable account for the long term.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research